BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers. It is expected to complete before end 2009.
By medicalnewstoday.com
Leave a Reply
You must be logged in to post a comment.
- EXCLUSIVE: Sen. Olympia Snowe Explains Her Lone ‘Yes’ to Health Care Bill
- ‘Mentally-ill’ Briton faces execution in China
- Iraq approves return of small British force
- Boyzone member death cause revealed
- Clinton: Russia yet to back Iran sanctions
- ‘Herminator’ Maier calls time on skiing career
- U.S. official: Turkey’s delay of exercise political
- Arrests of 10 linked to Basque separatists
- Bomber: I regret trying to kill Thatcher
- Unable to scream because her throat had been slit